An alternative, ‘MEKi-in-milk’ protocol, in which the drug is given to lactating mothers, has been employed effectively in mouse models of NF1 (Jecrois et al., 2021), and may represent a strategy to deliver MEK inhibitors at an earlier developmental stage in non-NF1 RASopathy models. Here, NF1 is linked to RASopathy.